106 related articles for article (PubMed ID: 37103444)
1. The Cost of Metastatic Prostate Cancer in the United States.
Olsen TA; Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2023 Jan; 10(1):41-47. PubMed ID: 37103444
[TBL] [Abstract][Full Text] [Related]
2. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
3. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016.
Mukherjee K; Small W; Duszak R
Brachytherapy; 2022; 21(1):12-21. PubMed ID: 34380592
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer.
Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
[TBL] [Abstract][Full Text] [Related]
5. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.
Horný M; Yabroff KR; Filson CP; Zheng Z; Ekwueme DU; Richards TB; Howard DH
Cancer; 2023 Oct; 129(20):3252-3262. PubMed ID: 37329254
[TBL] [Abstract][Full Text] [Related]
6. Cost of cancer management by stage at diagnosis among Medicare beneficiaries.
Reddy SR; Broder MS; Chang E; Paydar C; Chung KC; Kansal AR
Curr Med Res Opin; 2022 Aug; 38(8):1285-1294. PubMed ID: 35285354
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
8. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
9. The cost of glaucoma care provided to Medicare beneficiaries from 2002 to 2009.
Quigley HA; Cassard SD; Gower EW; Ramulu PY; Jampel HD; Friedman DS
Ophthalmology; 2013 Nov; 120(11):2249-57. PubMed ID: 23769330
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
[TBL] [Abstract][Full Text] [Related]
11. What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?
Mervin MC; Lowe A; Gardiner RA; Smith DP; Aitken J; Chambers SK; Gordon LG
Asia Pac J Clin Oncol; 2017 Jun; 13(3):152-159. PubMed ID: 28303657
[TBL] [Abstract][Full Text] [Related]
12. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract][Full Text] [Related]
13. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
14. Nonoperative care to manage sacroiliac joint disruption and degenerative sacroiliitis: high costs and medical resource utilization in the United States Medicare population.
Ackerman SJ; Polly DW; Knight T; Holt T; Cummings J
J Neurosurg Spine; 2014 Apr; 20(4):354-63. PubMed ID: 24527824
[TBL] [Abstract][Full Text] [Related]
15. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.
Aizer AA; Gu X; Chen MH; Choueiri TK; Martin NE; Efstathiou JA; Hyatt AS; Graham PL; Trinh QD; Hu JC; Nguyen PL
J Natl Compr Canc Netw; 2015 Jan; 13(1):61-8. PubMed ID: 25583770
[TBL] [Abstract][Full Text] [Related]
16. The burden of depression in prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Johnson JC; Gallo JJ
Psychooncology; 2012 Dec; 21(12):1338-45. PubMed ID: 21837637
[TBL] [Abstract][Full Text] [Related]
17. Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US.
Bhattacharya K; Bentley JP; Ramachandran S; Chang Y; Banahan BF; Shah R; Bhakta N; Yang Y
JAMA Netw Open; 2021 Jul; 4(7):e2116357. PubMed ID: 34241627
[TBL] [Abstract][Full Text] [Related]
18. Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015.
Wilson LE; Greiner MA; Altomare I; Rotter J; Dinan MA
J Geriatr Oncol; 2021 Apr; 12(3):375-380. PubMed ID: 33250425
[TBL] [Abstract][Full Text] [Related]
19. The cost implications of prostate cancer screening in the Medicare population.
Ma X; Wang R; Long JB; Ross JS; Soulos PR; Yu JB; Makarov DV; Gold HT; Gross CP
Cancer; 2014 Jan; 120(1):96-102. PubMed ID: 24122801
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
